Copy Link Print Information

cIAP1 Antibody (YA2500)

(Synonyms: cIAP1; C-IAP1; IAP homolog B; Inhibitor of apoptosis protein 2; IAP-2; hIAP-2; hIAP2; API1; IAP2; MIHB; RNF48)
Customer Review

Based on 1 Customer Validation

cIAP1 Antibody (YA2500) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to cIAP1.

For research use only. We do not sell to patients.
  • Host:

    Rabbit

  • Isotype:

    IgG

  • Application:

    WB, ICC/IF

  • Reactivity :

    Human

  • Formulation:

    Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% Sodium azide and 0.05% BSA

  • Conjugation:
    Non-conjugated
  • Experimental Validation Results for cIAP1 Antibody (YA2500)
  • cIAP1 Antibody (YA2500) Product Image
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Service
Data Download
Related Products:
You May Still Need
Top Publications Citing

Use of MCE Products

Applications

Application
WB Info
WB: Western Blot
ICC/IF Info
ICC/IF: Immunocytochemistry/
Immunofluorescence
Dilution Ratio 1:500-1:1000 1:50-1:200

Product Details

Description

cIAP1 Antibody (YA2500) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to cIAP1.

  • Host Rabbit
  • Clonality Recombinant,Monoclonal
  • Species Reactivity
    Human
  • Observed Molecular Weight
    Observed band size: 70 kDa Info
    Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
  • Calculated Molecular Weight Predicted band size: 70 kDa
Species Reactivity Database

Entrez Gene: 329 Human

SwissProt: Q13490 Human

Immunogen

A synthetic peptide of human cIAP1 aa29-42.

Sensitivity

Endogenous

Purification

Affinity Purified

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG

Product Properties

  • Appearance

    Solution

  • Formulation

    Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% Sodium azide and 0.05% BSA

  • Concentration

    Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration

  • Storage & Stability

    Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

  • Shipping

    Shipping with blue ice.

Verification Images

  • Experimental Validation Results for cIAP1 Antibody (YA2500)
    Western blot analysis was performed on extracts from HepG2 (lane 1, 15 μg), Jurkat (lane 2, 15 μg), Hela (lane 3, 15 μg), HT-29 (lane 4, 15 μg), A204 (lane 5, 15 μg), DU145 (lane 6, 15 μg) using cIAP1 Rabbit mAb.Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight.The primary antibody (1:1000 dilution) and the loading control antibody (beta-Tubulin, HY-P80955, 1:5000 dilution) were incubated in 5% non-fat milk in TBST for 1 hour at 37°C.Goat Anti-Rabbit IgG-HRP Secondary Antibody (1:20000 dilution) was then applied for 40 minutes at 37°C.

Background

  • Function

    Cellular inhibitor of apoptosis protein 1 (cIAP1) is a multifunctional E3 ubiquitin ligase that regulates apoptosis, NF-κB signaling, and cell proliferation in both cytoplasmic and nuclear compartments[1][4]. Mechanistically, cIAP1 modulates tumor necrosis factor receptor (TNFR) and pattern recognition receptor (PRR) signaling, thereby influencing innate immunity, inflammasome activation, and transcriptional control via E2F1[1][4][5][6]. Compared with cIAP2, cIAP1 exhibits distinct nuclear functions, including direct binding to E2F1 and enhancement of CCNE and CCNA gene transcription, which promotes cell cycle progression[4]. In disease models, cIAP1 contributes to tumor growth through interactions with TRAF2, activating the canonical NF-κB and JAK/STAT3 pathways, and sustaining survival in gallbladder cancer, non-small cell lung cancer, and skeletal muscle atrophy models[9][6][2][7]. Furthermore, cIAP1 is required for T cell costimulation through CD137 signaling, mediating NF-κB and MAPK activation, which is critical for antitumor immune responses[3]. Pharmacologically, cIAP1 degradation by SMAC mimetics or selective inhibitors potentiates apoptosis by releasing RIP1 and activating caspase complexes, highlighting its potential as a therapeutic target in cancer and immune-related diseases[8][3]. Overall, the unique nuclear and cytoplasmic functions of cIAP1 distinguish it from cIAP2, enabling diverse applications in experimental oncology, immunology, and tissue regeneration studies.

  • Subcellular Localization

    Cytoplasm; Nucleus

  • Expression


    Tissue_specificity:Present in many human tissues. Mainly expressed in human skeletal muscle, thymus, testis, ovary, and pancreas, low or absent in brain and peripheral blood leukocytes

  • Isoforms & Post-Translational Modification

    Q13490 has 2 isomers: Q13490-1: 69900 Da (predicted); Q13490-2: 64098 Da (predicted).
    Auto-ubiquitinated and degraded by the proteasome in apoptotic cells;Upon stimulation of death receptors, including TNFRSF10B, recruited to receptors and cleaved by caspases. Proteolytic fragments remain associated with the receptors. This cleavage presumably inactivates the protein

  • Subunit

    Interacts with DIABLO/SMAC and with PRSS25; these interactions inhibit apoptotic suppressor activity. Interacts with CASP9. Interacts (via BIR domains) with TRAF2; the interaction is required for IKBKE ubiquitination. Interacts with E2F1, RIPK1, RIPK2, RIPK3, RIPK4, BIRC5/survivin and USP19. HSP90AB1 (PubMed:25486457). Interacts with UBXN1 (PubMed:25681446). Interacts with GSK3B (PubMed:18846110). Interacts with several death receptors, inclusing FAS, TNFRSF10A and TNFRSF10B (PubMed:18846110). Recruited to TNFRSF10B in the absence of receptor stimulation. When TNFRSF10B is stimulated, further recruited to the receptor and cleaved by caspases. Proteolytic fragments remain associated with TNFRSF10B (PubMed:18846110)

  • SwissProt ID

    Q13490

  • Gene ID
    329 [NCBI]
  • Synonyms

    cIAP1; C-IAP1; IAP homolog B; Inhibitor of apoptosis protein 2; IAP-2; hIAP-2; hIAP2; API1; IAP2; MIHB; RNF48

  • Research Field

    Cell Biology

[1]. Zadoroznyj A, et al. Cytoplasmic and Nuclear Functions of cIAP1. Biomolecules. 2022 Feb 17;12(2):322. [Content Brief]

[2]. Su W, et al. cIAP1 promotes proliferation and migration and prevents apoptosis in gallbladder cancer in vitro. Biosci Rep. 2019 Apr 12;39(4):BSR20182266. [Content Brief]

[3]. Glez-Vaz J, et al. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects. Sci Adv. 2023 Aug 18;9(33):eadf6692. [Content Brief]

[4]. Cartier J, et al. Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription. J Biol Chem. 2011 Jul 29;286(30):26406-17. [Content Brief]

[5]. Labbé K, et al. Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome. Immunity. 2011;35(6):897-907.

[6]. Bertrand MJM, et al. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity. 2009;30(6):789-801.

[7]. Vu NT, et al. Caspase-9b Interacts Directly with cIAP1 to Drive Agonist-Independent Activation of NF-κB and Lung Tumorigenesis. Cancer Res. 2016 May 15;76(10):2977-89. [Content Brief]

[8]. Yang C, et al. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC. J Exp Clin Cancer Res. 2016 Sep 30;35(1):158. [Content Brief]

[9]. Zhang J, et al. Ubiquitin Ligases cIAP1 and cIAP2 Limit Cell Death to Prevent Inflammation. Cell Rep. 2019 May 28;27(9):2679-2689.e3. [Content Brief]

[10]. Dumétier B, et al. IAP-Mediated Protein Ubiquitination in Regulating Cell Signaling. Cells. 2020 Apr 30;9(5):1118. [Content Brief]

[11]. Morrish E, et al. Future Therapeutic Directions for Smac-Mimetics. Cells. 2020 Feb 11;9(2):406. [Content Brief]

View More

cIAP1 Antibody (YA2500) Related Classifications

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated CTLL-2 mouse cytotoxic T cells. The ED50 this effect is 0.8023 μg/ml, corresponding to a specific activity is 1246.42 units/mg.

Assay Types
  • 1/16

    MedchemExpress Validation
     Western blot analysis was performed on extracts from HepG2 (lane 1, 15 μg), Jurkat (lane 2, 15 μg), Hela (lane 3, 15 μg), HT-29 (lane 4, 15 μg), A204 (lane 5, 15 μg), DU145 (lane 6, 15 μg) using cIAP1 Rabbit mAb.Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight.The primary antibody (1:1000 dilution) and the loading control antibody (beta-Tubulin, HY-P80955, 1:5000 dilution) were incubated in 5% non-fat milk in TBST for 1 hour at 37°C.Goat Anti-Rabbit IgG-HRP Secondary Antibody (1:20000 dilution) was then applied for 40 minutes at 37°C.

  • cIAP1 Antibody (YA2500) Product Image
    1/16
  • Experimental Validation Results for cIAP1 Antibody (YA2500)
  • cIAP1 Antibody (YA2500) Product Image
  • Experimental Validation Results for cIAP1 Antibody (YA2500)
    1/1
    MedchemExpress Validation
     Western blot analysis was performed on extracts from HepG2 (lane 1, 15 μg), Jurkat (lane 2, 15 μg), Hela (lane 3, 15 μg), HT-29 (lane 4, 15 μg), A204 (lane 5, 15 μg), DU145 (lane 6, 15 μg) using cIAP1 Rabbit mAb.Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight.The primary antibody (1:1000 dilution) and the loading control antibody (beta-Tubulin, HY-P80955, 1:5000 dilution) were incubated in 5% non-fat milk in TBST for 1 hour at 37°C.Goat Anti-Rabbit IgG-HRP Secondary Antibody (1:20000 dilution) was then applied for 40 minutes at 37°C.
  • Experimental Validation Results for cIAP1 Antibody (YA2500)
  • cIAP1 Antibody (YA2500) Product Image
    MedchemExpress Validation

    Western blot analysis was performed on extracts from HepG2 (lane 1, 15 μg), Jurkat (lane 2, 15 μg), Hela (lane 3, 15 μg), HT-29 (lane 4, 15 μg), A204 (lane 5, 15 μg), DU145 (lane 6, 15 μg) using cIAP1 Rabbit mAb.Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight.The primary antibody (1:1000 dilution) and the loading control antibody (beta-Tubulin, HY-P80955, 1:5000 dilution) were incubated in 5% non-fat milk in TBST for 1 hour at 37°C.Goat Anti-Rabbit IgG-HRP Secondary Antibody (1:20000 dilution) was then applied for 40 minutes at 37°C.

  • cIAP1 Antibody (YA2500) Product Image WB